- About Us
-
Our Business
-
- Therapeutic Areas Our portfolio is diverse and based upon - Market Research, Regulatory & IP.
- Licensing Licensing activities are excellent opportunities for companies to expand their portfolio.
- Biosimilar Biosimilar are biologic medicines that are developed to match their reference medicine.
-
- CRAM India has grown to be one of the key nations complying GMP manufacturing norms.
- Medical Devices REVA help our clients to deliver customized, cost-effective medical device value chain.
-
API
-
Dosage form
-
-
Operations
- At Reva, we have requisite infrastructure, with a balanced reach across Regulated, Emerging & Expansion markets. And we are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
-
Research & Development
-
Manufacturing
-
Quality
- Media
- Contact us
May 14, 2021
Dr. Gurpreet Sandhu on TEZ
May 9, 2021
Dr. Sandhu on Duty Towards Health Professionals
May 9, 2021
Dr. Gurpreet Sandhu on Indian Vaccine Drive
Mar 23, 2021
Dr. Gurpreet Sandhu's Keynote Address -
National Pharma Tech Connect, 2021
National Pharma Tech Connect, 2021
Jan 11, 2021
Dr. Gurpreet Sandhu on Primetime ABP
Jan 8, 2018
Dr. Gurpreet Sandhu - GLOBAL HEALTHCARE SUMMIT
Dec 17, 2015
Dr. Gurpreet Sandhu Emerging Markets - at MADRID CPhl
Nov 6, 2015
re-Connect Congress Dr Gurpreet Sandhu Emerging Markets Outlook
Dec 13, 2014
API Sourcing in Emerging Markets Pre-Connect Congress CPhI WW 2014
Nov 21, 2014
Dr. Gurpreet Sandhu : Global Pharmaceutical Industry and Generic Industry